US20120058983A1 - Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension - Google Patents

Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension Download PDF

Info

Publication number
US20120058983A1
US20120058983A1 US13/210,889 US201113210889A US2012058983A1 US 20120058983 A1 US20120058983 A1 US 20120058983A1 US 201113210889 A US201113210889 A US 201113210889A US 2012058983 A1 US2012058983 A1 US 2012058983A1
Authority
US
United States
Prior art keywords
hydrogen
methyl
ethyl
sulfanyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/210,889
Other languages
English (en)
Inventor
Jürgen Klar
Georges von Degenfeld
Hans-Georg Lerchen
Barbara Albrecht-Küpper
Andreas Knorr
Peter Sandner
Daniel Meibom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of US20120058983A1 publication Critical patent/US20120058983A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the use in a method for the treatment and/or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and/or combinations thereof as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and/or combinations thereof.
  • Glaucoma is a degenerative disease comprising a group of debilitating eye diseases that are a leading cause of permanent loss of visual function due to irreversible damage to the optical nerve. Glaucoma refers further to a disease of the eye, characterized and caused by damage of the optic nerve head, degeneration of ocular tissues, and/or elevated intraocular pressure. There are several functionally or morphologically distinct types of glaucoma which in general are accompanied by elevated intraocular pressure (IOP).
  • IOP intraocular pressure
  • the increased IOP is considered to be causally related to the pathological progress of the disease.
  • intraocular pressure is elevated but no apparent loss of visual function has occurred. These patients are considered to be at high risk for a potential development of visual loss associated with glaucoma.
  • Some patients which show a glaucomatous vision field loss have a normal to low intraocular pressure. These so called normotension or low tension glaucoma patients can also benefit form agents that decrease intraocular pressure.
  • the loss of visual function and the progressive deterioration associated with glaucoma and ocular hypertension can generally be ameliorated with medications that reduce elevated intraocular hypertension when glaucoma or ocular hypertension is detected early.
  • Glaucoma on the basis of its etiology—refers also to primary or secondary glaucoma.
  • Primary glaucoma in adults (congenital glaucoma) may be either open-angle or acute or chronic angle-closure.
  • Primary glaucoma is characterized by increased intraocular tension which is due to the obstruction of aqueous humor outflow.
  • POAG chronic open-angle glaucoma
  • the anterior chamber and its anatomic structures appear normal, but drainage of the aqueous humor is hampered.
  • acute or chronic angle-closure the filtration angle is narrowed, the anterior chamber is shallow and the iris may obstruct the trabecular meshwork at the entrance of the canal of Schlemm. Dilation of the pupil may push the root of the iris forward against the angle, and may produce pupilary block and thus precipitate an acute attack.
  • a predisposion to acute angle—closure glaucoma attacks with various degrees of severity is know in patients eyes with narrow anterior chamber angles
  • Secondary glaucoma is characterized and caused by any interference which effects the flow of aqueous humor from the posterior chamber into the anterior chamber and subsequently, into the canal of Schlemm.
  • inflammatory disease of the anterior segment may inhibit aqueous outflow by causing complete posterior synechia in iris bombe and may plug the drainage channel with exudates.
  • Other common causes are intraocular tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures and intraocular hemorrhage.
  • Adenosine a purine nucleoside
  • Adenosine is an ubiquitous modulator of numerous physiological activities which is mediated by specific cell surface receptors.
  • Adenosine is formed intracellularly as an intermediate during the degradation of adenosine 5′-monophosphate (AMP) and S-adenosylhomocysteine, but it can be released from the cell, in which case it acts as a hormone-like substance or neurotransmitter by binding to specific receptors.
  • AMP adenosine 5′-monophosphate
  • S-adenosylhomocysteine S-adenosylhomocysteine
  • A1 A2a, A2b and A3
  • adenosine-receptor-selective ligands are substances which bind selectively to one or more subtypes of the adenosine receptors, thus either mimicking the action of adenosine (adenosine agonists) or blocking its action (adenosine antagonists).
  • adenosine receptors are mediated intracellularly by the messenger cAMP.
  • the intracellular cAMP is increased via activation of the membrane-bound adenylate cyclase, whereas binding of adenosine to the A1 or A3 receptors results in a decrease of the intracellular cAMP concentration via inhibition of adenylate cyclase.
  • adenosine receptors In the cardiovascular system, the main consequences of the activation of adenosine receptors are: bradycardia, negative inotropism and protection of the heart against ischemia (“preconditioning”) via A1 receptors, dilation of the blood vessels via A2a and A2b receptors and inhibition of the fibroblasts and smooth-muscle-cell proliferation via A2b receptors.
  • preconditioning via A1 receptors
  • dilation of the blood vessels via A2a and A2b receptors dilation of the blood vessels via A2a and A2b receptors and inhibition of the fibroblasts and smooth-muscle-cell proliferation via A2b receptors.
  • A1 agonists coupled preferably via G, proteins
  • a decrease of the intracellular cAMP concentration is observed (preferably after direct prestimulation of adenylate cyclase by forskolin).
  • A2a and A2b agonists (coupling preferably via G, proteins) leads to an increase and A2a and A2b antagonists to a decrease of the cAMP concentration in the cells.
  • A2 receptors a direct prestimulation of adenylate cyclase by forskolin is of no benefit.
  • A1 receptors In humans, activation of A1 receptors by specific A1 agonists leads to a frequency-dependent lowering of the heart rate, without any effect on blood pressure.
  • Selective A1 agonists may thus be suitable inter alia for treating angina pectoris and atrial fibrillation.
  • the cardioprotective action of the A1 receptors in the heart may be utilized inter alia by activating these A1 receptors with specific A1 agonists for treatment and organ protection in cases of acute myocardial infarction, acute coronary syndrome, heart failure, bypass operations, heart catheter examinations and organ transplantations.
  • adenosine A1 receptor agonists For the adenosine A1 receptor several subtype specific agonists have been reported like NNC-21-0126, GR79236, selodenoson and capadenoson which have been reported to be in clinical development (Lit. 5). Also the effect of adenosine A1 receptor agonists on intraocular pressure has been intensively studied and characterized. It was shown that two relatively selective adenosine A1 agonists N6-cyclohexyl-adenosine (CHA) and R( ⁇ )-N-6-(2-phenylisopropyl)adenosine (R-PIA) lower intraocular pressure in rabbits (Lit. 6,7,8) and cynomolgus monkeys (Lit. 9).
  • CHA cyclohexyl-adenosine
  • R-PIA R( ⁇ )-N-6-(2-phenylisopropyl)adenosine
  • adenosine A1 agonists as therapeutic drugs for glaucoma or ocular hypertension is significantly limited by the effects on hemodynamic parameters as it is known that adenosine A1 agonists are crucially involved in heart rate and blood pressure regulation (Lit. 10).
  • the object of the present invention is to provide an effective therapeutic agent for the treatment and/or prophalxis of glaucoma and/or ocular hypertension without showing the above mentioned side effects.
  • dicyanopyridines of formula (I) lower intraocular pressure without effecting hemodynamics and are thus suitable for the production of medicaments for the treatment and/or prophylaxis of glaucoma and ocular hypertension.
  • the present invention relates to compounds of formula (I)
  • R 1 is hydrogen or a group of the formula
  • R 1 is defined as above
  • R 3 is hydrogen, methyl or ethyl
  • R 4 is hydrogen, methyl or ethyl
  • R 3 and R 4 form together with the nitrogen-atom, which they are bound to, a azetidine-pyrrolidine- or piperidine-ring
  • the present invention relates to compounds of formula (I), in which
  • A is sulfur
  • R 1 is a group of the formula
  • the present invention also relates to compounds of formula (I), in which
  • A is sulfur
  • R 1 is a group of the formula
  • the present invention relates to a compound of the formula (I) selected from:
  • the present invention also relates to compounds of formula (I), in which
  • R 3 is hydrogen
  • R 4 is hydrogen
  • its salts, solvates and solvates of the salts for the use in a method treatment and/or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and/or combinations thereof.
  • the present invention also relates to compounds of formula (I), in which
  • R 3 and R 4 form together with the nitrogen-atom, which they are bound to, a azetidine-pyrrolidine- or piperidine-ring, and its salts, solvates and solvates of the salts, for the use in a method treatment and/or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and/or combinations thereof.
  • the compounds of formula (I), their production and their action as potent and selective adenosine A1 agonists are disclosed in WO 03/53441, WO 2009/015776, WO 2009/015811, WO 2009/015812, WO 2010/072314, WO 2010/072315 and WO 2010/086101 respectively.
  • the compounds mentioned in WO 03/53441, WO 2009/015776, WO 2009/015811, WO 2009/015812, WO 2010/072314, WO 2010/072315 and WO 2010/086101 in general and especially the compounds specifically are explicit part of the description of the present invention.
  • the compounds of the formula (I) can exist in stereoisomeric forms, which behave either as image and mirror image (enantiomers) or which do not behave as image and mirror image (diastereomers).
  • the invention relates both to the use of the enantiomers or diastereomers and to their respective mixtures. Just like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner Equally, the present invention also relates to the use of the other tautomers of the compounds of the formula (I) and their salts.
  • Salts of the compounds of the formula (I) can be physiologically acceptable salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
  • Particularly preferred salts are, for example, those with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, trifluoroacetic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
  • the compounds of the present invention appear preferably as hydrochlorides or trifluoroacetates.
  • Salts which can be mentioned are also salts with customary bases, such as, for example, alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts (e.g. calcium or magnesium salts) or ammonium salts, derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmorpholine, dihydro-abietylamine, 1-ephenamine or methylpiperidine.
  • alkali metal salts e.g. sodium or potassium salts
  • alkaline earth metal salts e.g. calcium or magnesium salts
  • ammonium salts derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmorpholine, dihydro-
  • Hydrates or solvates are designated according to the invention as those forms of the compounds of the formula (I) which in the solid or liquid state form a molecular compound or a complex by hydration with water or coordination with solvent molecules.
  • Examples of hydrates are sesqui-hydrates, monohydrates, dihydrates or trihydrates. Equally, the hydrates or solvates of salts of the compounds according to the invention are also suitable.
  • Alkyl is in the context of the invention a straight-chain or branched alkyl radical having 1 to 4 carbon atoms.
  • the following radicals may be mentioned by way of example and by way of preference: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • Alkanediyl is in the context of the invention a straight-chain or branched divalent alkyl radical having 1 to 4 carbon atoms.
  • Examples which may be preferably mentioned are: ethane-1,2-diyl (1,2-ethylene), ethane-1,1-diyl, propane-1,3-diyl (1,3-propylene), propane-1,1-diyl, propane-1,2-diyl, propane-2,2-diyl, butane-1,4-diyl (1,4-butylene), butane-1,2-diyl, butane-1,3-diyl, butane-2,3-diyl.
  • Alkoxy is in the context of the invention a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms.
  • Mono- or di-(C 1 -C 4 )-alkylamino is in the context of the invention an amino group having one or having two identical or different straight-chain or branched alkyl substituents, which in each case contain 1 to 4 carbon atoms.
  • the side group of an ⁇ -amino acid in the meaning of R 3 encompasses both the side groups of naturally occurring ⁇ -amino acids and the side groups of homologs and isomers of these ⁇ -amino acids.
  • the ⁇ -amino acid may in this connection have both the L and the D configuration or else be a mixture of the L form and D form.
  • side groups which may be mentioned are: methyl (alanine), propan-2-yl (valine), propan-1-yl (norvaline), 2-methylpropan-1-yl (leucine), 1-methylpropan-1-yl (isoleucine), butan-1-yl (norleucine), tert-butyl (2-tert-butylglycine), phenyl (2-phenylglycine), benzyl (phenylalanine), p-hydroxybenzyl (tyrosine), indol-3-ylmethyl (tryptophan), imidazol-4-ylmethyl (histidine), hydroxymethyl (serine), 2-hydroxyethyl (homoserine), 1-hydroxyethyl (threonine), mercaptomethyl (cysteine), methylthiomethyl (S-methylcysteine), 2-mercaptoethyl (homocysteine), 2-methylthioethyl (methionine), carbamo
  • Preferred ⁇ -amino acid side groups in the meaning of R 3 are methyl (alanine), propan-2-yl (valine), 2-methylpropan-1-yl (leucine), benzyl (phenylalanine), imidazol-4-ylmethyl (histidine), hydroxymethyl (serine), 1-hydroxyethyl (threonine), 4-aminobutan-1-yl (lysine), 3-aminopropan-1-yl (ornithine), 2-aminoethyl (2,4-diaminobutyric acid), aminomethyl (2,3-diaminopropionic acid), 3-guanidinopropan-1-yl (arginine).
  • the L configuration is preferred in each case.
  • the present invention relates to selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the use in a method for the treatment and/or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and/or combinations thereof.
  • the compounds of formula (I) act as selective adenosine A1 agonists and show a beneficial profile when administered topically to the eye, and are thus useful as an effective therapeutic agent for the treatment and/or prophylaxis of glaucoma and/or ocular hypertension.
  • the present invention relates to compounds of formula (I) for the use in a method for the treatment and/or prophylaxis of glaucoma and/or ocular hypertension.
  • the present invention relates to compounds of formula (I) for the use in a method for the treatment and/or prophylaxis of high IOP resulting from traumatic hyphema, orbital edema, postoperative visco-elastic retention, intraocular inflammation, corticosteroid use, pupillary block, or idiopathic causes.
  • the compounds of formula (I) are useful for the treatment and/or prophylaxis of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes and as presurgical adjuncts.
  • the present invention further relates to a method of treating glaucoma, or other disease or disorder of the eye related to elevated intraocular pressure.
  • the present invention further relates to the use of compounds of formula (I) for the manufacture of medicaments for the treatment and/or prophylaxis of glaucoma and/or ocular hypertension.
  • a further subject of the present invention is a pharmaceutical composition comprising a compound of the formula (I).
  • a further subject of the present invention is the use of a combination of one or more compounds of the formula (I) with one or more other active compounds in a method for the treatment and/or prophylaxis of glaucoma, high IOP resulting from traumatic hyphema, orbital edema, postoperative visco-elastic retention, intraocular inflammation, corticosteroid use, pupillary block, or idiopathic causes.
  • suitable combination active ingredients may for example and preferably be mentioned:
  • a method for the treatment and/or prophylaxis of high IOP including glaucoma, ocular hypertension, normotensive glaucoma or a combination thereof comprising administering an effective amount at least one compound of formula (I) or of a medicament comprising at least one compound of formula (I) in combination with an inert, non-toxic, pharmaceutically suitable excipent to the eye.
  • Preferred administration route is topical administration to the eye.
  • Topical preparations of the invention include solutions, sprays, lotions, gels, creams, powders, powder sprays, pastes, emulsions, foams and sticks which comprise the active ingredient of the formula (I), where appropriate also a plurality of active ingredients.
  • Suitable pharmaceutically-acceptable carriers for topical application include those suited for use in lotions, creams, gels, solutions, ointments, viscous solutions, eye drops, emulsions, gel-forming solutions and the like.
  • topically applicable preparations of the invention comprise 0.1 to 99%, preferably 0.5 to 20% by weight of active ingredient of the formula (I).
  • Ointments comprise hydrocarbon gels, lipogels, absorption bases, W/O ointment bases, mixed emulsions or polyethylene glycols as base.
  • Gels comprise solvents such as water, ethanol, isopropanol or propylene glycol and are produced using gel formers such as cellulose ethers, alginates, polyacrylates, bentonite, gelatin, tragacanth, polyvinylpyrrolidone or polyvinyl alcohol. Lipophilic gel bases or microemulsions can also be used.
  • the composition is sterile and can be in dosage unit form, e.g., suitable for topical ocular use.
  • the composition can be packaged in a form suitable for metered application, such as in container equipped with a dropper.
  • compositions of the invention are a solution prepared using a physiological saline solution as a carrier.
  • the pH of the solution is, preferably, maintained between 4.5 and 8.0 using an appropriate buffer system.
  • a neutral pH is more preferred.
  • Compositions of the invention can also comprise pharmaceutically acceptable preservatives, stabilizers and/or surfactants.
  • the active compounds can be converted into the customary preparations in a manner known per se. This takes place using inert, nontoxic, pharmaceutically suitable carriers, excipients, solvents, vehicles, emulsifiers and/or dispersants.
  • Suitable excipients which may be mentioned are, for example: water, nontoxic organic solvents such as, for example, paraffins, vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol, glycerol), glycols (e.g. polyethylene glycol), solid carriers such as natural or synthetic ground minerals (e.g. talc or silicates), sugars (e.g. lactose), emulsifiers, dispersants (e.g. polyvinylpyrrolidone) and glidants (e.g. magnesium sulfate).
  • nontoxic organic solvents such as, for example, paraffins, vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol, glycerol), glycols (e.g. polyethylene glycol), solid carriers such as natural or synthetic ground minerals (e.g. talc or silicates), sugars (e.g. lactose), emulsifiers, dispersants (e.
  • the test compounds were diluted in 0.9% sodium chloride and given by topical administration to the eye in 10 ⁇ l volume at a concentration of 10 mg/ml.
  • IOP was measured with a rebound tonometer (TonoLab) at different time points after application of the drugs. Ocular pressure and effects of hemodynamic parameters can be monitored in this model.
  • FIG. 1 shows IOP of N 6 -Cyclopentyl-Adenosine and Example 1 at a dose of 10 mg/ml.
  • FIG. 2 shows effects of N 6 -Cyclopentyl-Adenosine and Example 1 at a dose of 10 mg/ml on mean arterial blood pressure.
  • N 6 -Cyclopentyl-Adenosine and Example 1 reduce IOP at a volume of 10 ⁇ l (concentration 10 mg/ml). Surprisingly, Example 1 shows no effect on hemodynamic parameters at 10 mg/ml. However N 6 -Cyclopentyl-Adenosine significantly reduces blood pressure ( FIG. 2 ).
  • a fluid-filled sensor catheter was inserted upstream into the exposed descending aorta between the iliac bifurcation and the renal arteries.
  • the tip of the telemetric catheter was located just caudal to the renal arteries and secured by tissue adhesive.
  • the transmitter body was affixed to the inner peritoneal wall before closure of abdomen.
  • each rat cage was positioned on top of an individual receiver platform.
  • mice (all at least 7 weeks old) were deeply anesthetized, and optic nerves were intraorbitally crushed. After treating the mice for two weeks with compounds, i.e. the adenosine A1 agonists they were sacrificed and eyes were withdrawn. Flatmounts of the retinas were prepared. The degenerated retinal ganglion cells were analyzed and counted in the different treatment groups.
  • compounds i.e. the adenosine A1 agonists they were sacrificed and eyes were withdrawn.
  • Flatmounts of the retinas were prepared.
  • the degenerated retinal ganglion cells were analyzed and counted in the different treatment groups.
  • mice Male Lewis rats weighing 200 to 250 g and male C57BL/6J mice weighing 25 to 30 g were anesthetized.
  • the anterior chamber of one eye was cannulated with a needle attached to a line infusing normal saline to increase intraocular pressure.
  • IOP was measured by a handheld tonometer (TonoLab) in rat eyes for the next up to 120 minutes. The other eye of the same animal was set up as a control. After ischemia, the needle was withdrawn, IOP was normalized, and reflow of the retinal circulation was documented visually. Animals were killed at different times after I/R injury.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
US13/210,889 2010-09-02 2011-08-16 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension Abandoned US20120058983A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175151 2010-09-02
EP10175151.9 2010-09-02

Publications (1)

Publication Number Publication Date
US20120058983A1 true US20120058983A1 (en) 2012-03-08

Family

ID=44582992

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/210,889 Abandoned US20120058983A1 (en) 2010-09-02 2011-08-16 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US13/819,790 Expired - Fee Related US9040566B2 (en) 2010-09-02 2011-08-29 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US14/705,967 Abandoned US20150306084A1 (en) 2010-09-02 2015-05-07 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/819,790 Expired - Fee Related US9040566B2 (en) 2010-09-02 2011-08-29 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US14/705,967 Abandoned US20150306084A1 (en) 2010-09-02 2015-05-07 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension

Country Status (30)

Country Link
US (3) US20120058983A1 (es)
EP (1) EP2611415B1 (es)
JP (1) JP5875585B2 (es)
KR (1) KR20140091457A (es)
CN (1) CN103249400B (es)
AP (1) AP3413A (es)
AU (1) AU2011298430B2 (es)
BR (1) BR112013005224A2 (es)
CA (1) CA2809700A1 (es)
CL (2) CL2013000599A1 (es)
CR (1) CR20130094A (es)
CY (1) CY1117458T1 (es)
DK (1) DK2611415T3 (es)
EA (1) EA028411B1 (es)
ES (1) ES2570659T3 (es)
HK (1) HK1188138A1 (es)
HR (1) HRP20160532T1 (es)
HU (1) HUE027295T2 (es)
MA (1) MA34489B1 (es)
MX (1) MX2013002396A (es)
MY (1) MY160383A (es)
NZ (1) NZ607624A (es)
PL (1) PL2611415T3 (es)
RS (1) RS54743B1 (es)
SG (1) SG187974A1 (es)
SI (1) SI2611415T1 (es)
TW (1) TWI516266B (es)
UA (1) UA111947C2 (es)
WO (1) WO2012028585A1 (es)
ZA (1) ZA201302340B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806314B2 (en) 2013-12-09 2023-11-07 Respira Therapeutics, Inc. PDE5 inhibitor powder formulations and methods relating thereto

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2807178T1 (sl) 2012-01-26 2017-09-29 Inotek Pharmaceuticals Corporation Anhidridni polimorf (2R,3S,4R,5R)-5-(6-(ciklofentilamino)-9H-purin-9-il)-3,4-dihidroksite- trahidrofuran-2-il))metil nitrat in postopki njegove priprave
JP2016539986A (ja) * 2013-12-12 2016-12-22 バイエル ファーマ アクチエンゲゼルシャフト 腎疾患に対する薬剤としてのアデノシンａ１アゴニスト
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
CA2984984A1 (en) * 2015-05-06 2016-12-01 Bayer Pharma Aktiengesellschaft Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus
CN112545983A (zh) * 2020-12-18 2021-03-26 合肥中龙神力动物药业有限公司 一种复方硫酸新霉素滴眼液及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053441A1 (de) * 2001-12-11 2003-07-03 Bayer Healthcare Ag Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052510A (en) 1974-12-18 1977-10-04 Sandoz, Inc. 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (es) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
DE4334919A1 (de) * 1993-10-13 1995-04-20 Liedtke Pharmed Gmbh Grenzwertig wirksame Arzneiformen mit Betablockern
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
DE4430638A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
ATE548351T1 (de) 1996-01-29 2012-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten
JPH10324687A (ja) 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
WO1998054139A1 (de) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
HUP0300029A2 (en) 2000-02-25 2003-05-28 Hoffmann La Roche Adenosine receptor modulators, pharmaceutical compositions containing them and their use
WO2002006237A1 (fr) 2000-07-18 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Medicament comprenant un derive de dicyanopyridine
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1341772A2 (en) 2000-12-11 2003-09-10 E. I. du Pont de Nemours and Company Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja) 2001-12-20 2003-07-03 Yamanouchi Pharmaceut Co Ltd ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
MXPA05006367A (es) 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004275719B2 (en) 2003-09-23 2010-08-19 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
BRPI0512514A (pt) 2004-06-25 2008-03-11 Taisho Pharmaceutical Co Ltd composto, antagonista para receptores de crf, e, uso de um composto
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
WO2006034446A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
EP1863482A1 (en) 2005-03-24 2007-12-12 Bayer HealthCare AG Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
AU2007246172A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors 3
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007036075A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
EP2297104B1 (de) 2008-05-29 2013-08-07 Bayer Intellectual Property GmbH 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008062561A1 (de) * 2008-12-16 2010-06-24 Maxon Motor Ag Bausatz für einen Elektromotor mit einem Drehwinkelgeber
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
NZ596428A (en) * 2009-05-01 2014-03-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053441A1 (de) * 2001-12-11 2003-07-03 Bayer Healthcare Ag Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Crossen, C., Investigative Ophthalmology & Visual Science, 2001, vol. 42, pp 1837-40 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806314B2 (en) 2013-12-09 2023-11-07 Respira Therapeutics, Inc. PDE5 inhibitor powder formulations and methods relating thereto

Also Published As

Publication number Publication date
WO2012028585A1 (en) 2012-03-08
PL2611415T3 (pl) 2016-08-31
DK2611415T3 (en) 2016-05-23
AU2011298430A1 (en) 2013-03-21
UA111947C2 (uk) 2016-07-11
CA2809700A1 (en) 2012-03-08
JP2013536819A (ja) 2013-09-26
CL2016001164A1 (es) 2016-12-23
HK1188138A1 (en) 2014-04-25
HRP20160532T1 (hr) 2016-06-17
CY1117458T1 (el) 2017-04-26
BR112013005224A2 (pt) 2016-05-03
MX2013002396A (es) 2013-04-03
TW201212926A (en) 2012-04-01
ZA201302340B (en) 2015-11-25
EA028411B1 (ru) 2017-11-30
RS54743B1 (sr) 2016-10-31
AP3413A (en) 2015-09-30
US20150306084A1 (en) 2015-10-29
SG187974A1 (en) 2013-04-30
CN103249400A (zh) 2013-08-14
US9040566B2 (en) 2015-05-26
TWI516266B (zh) 2016-01-11
AU2011298430B2 (en) 2015-02-26
CN103249400B (zh) 2015-04-22
MY160383A (en) 2017-03-15
SI2611415T1 (sl) 2016-06-30
US20130210797A1 (en) 2013-08-15
EA201300310A1 (ru) 2013-08-30
CR20130094A (es) 2013-07-01
EP2611415B1 (en) 2016-02-24
HUE027295T2 (en) 2016-10-28
KR20140091457A (ko) 2014-07-21
JP5875585B2 (ja) 2016-03-02
MA34489B1 (fr) 2013-08-01
ES2570659T3 (es) 2016-05-19
EP2611415A1 (en) 2013-07-10
AP2013006753A0 (en) 2013-02-28
CL2013000599A1 (es) 2013-08-09
NZ607624A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
US20150306084A1 (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
JP6865254B2 (ja) 眼疾患を処置するための組成物、製剤、および方法
US10858354B2 (en) HPTP-Beta inhibitors
EP2156833B1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
ES2798138T3 (es) Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
EP2526094B1 (en) Substituted chlorocyclopentanols for therapeutic applications
JP2013531063A (ja) 二官能基Ｒｈｏキナーゼ阻害化合物、組成物およびその使用
KR20100131976A (ko) 고 안압증의 치료를 위한 디플루오로바이페닐아미드 유도체
JP2019523260A (ja) キラルペプチド
US20070049625A1 (en) EP2 receptor agonists for treating glaucoma
WO2019124489A1 (ja) セペタプロストとｅｐ２アゴニストとの組み合わせ医薬
US20160220677A1 (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
US11666563B2 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
WO2011149012A1 (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用
JPWO2019065838A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬
US20100190834A1 (en) Composition for ophtalmic disease associated with hypoxia or ischemia
WO2013114397A2 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
KR20200103041A (ko) 오미데네팍의 조합
JPWO2021158663A5 (es)

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION